We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+17.28%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11B
AUM Growth
+$1.48B
Cap. Flow
-$1.03B
Cap. Flow %
-9.36%
Top 10 Hldgs %
83.4%
Holding
140
New
7
Increased
14
Reduced
16
Closed
6

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$55.6M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$44.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$40.8M
4
NGNE icon
Neurogene
NGNE
+$28.1M
5
EXEL icon
Exelixis
EXEL
+$25.4M

Top Sells

Rank Stock Value
1
XNPT
XENOPORT, INC.
XNPT
+$24.5M
2
MDVN
MEDIVATION, INC.
MDVN
+$19.9M
3
NVAX icon
Novavax
NVAX
+$17.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$16.2M
5
INSM icon
Insmed
INSM
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 88.07%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITCI
51
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.28M 0.08%
609,166
– –
IMGN
52
DELISTED
Immunogen Inc
IMGN
$8.08M 0.07%
3,015,353
– –
LGND icon
53
Ligand Pharmaceuticals
LGND
$5.71B
$7.49M 0.07%
117,638
– –
ALDR
54
DELISTED
Alder Biopharmaceuticals
ALDR
$7.12M 0.06%
217,328
– –
RARE icon
55
Ultragenyx Pharmaceutical
RARE
$2.55B
$7.09M 0.06%
100,000
-10,894
-10% -$695K
TRIL
56
DELISTED
Trillium Therapeutics Inc.
TRIL
$6.12M 0.06%
413,697
+201,905
+95% +$2.32M
INSM icon
57
Insmed
INSM
$27.5B
$5.81M 0.05%
400,000
-1,100,000
-73% -$13.8M
ARCT icon
58
Arcturus Therapeutics
ARCT
$382M
$5.77M 0.05%
333,766
– –
PRQR icon
59
ProQR Therapeutics
PRQR
$330M
$5.74M 0.05%
860,464
-373,631
-30% -$2.06M
NDRM
60
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$5.64M 0.05%
305,000
– –
CPRX
61
DELISTED
Catalyst Pharmaceutical
CPRX
$5.56M 0.05%
5,102,153
-20,000
-0.4% -$18K
NTRA icon
62
Natera
NTRA
$47.9B
$5M 0.05%
450,000
– –
GNMX
63
DELISTED
Aevi Genomic Medicine Inc
GNMX
$4.91M 0.04%
880,539
– –
AKTX
64
Akari Therapeutics
AKTX
$15.3M
$4.23M 0.04%
621
– –
NERV icon
65
Minerva Neurosciences
NERV
$231M
$3.65M 0.03%
32,351
-31,200
-49% -$3.03M
STML
66
DELISTED
Stemline Therapeutics, Inc.
STML
$3.61M 0.03%
333,497
– –
LOXO
67
DELISTED
Loxo Oncology, Inc
LOXO
$3.61M 0.03%
137,735
– –
RXDX
68
DELISTED
Ignyta, Inc.
RXDX
$3.59M 0.03%
571,000
– –
VIRX
69
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.24M 0.03%
21,190
– –
CNCE
70
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$3.21M 0.03%
316,976
-153,082
-33% -$1.67M
TRVN
71
DELISTED
Trevena, Inc.
TRVN
$3.04M 0.03%
720
– –
SYRS
72
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.84M 0.03%
20,447
– –
ADMS
73
DELISTED
Adamas Pharmaceuticals
ADMS
$2.83M 0.03%
172,630
– –
TARA icon
74
Protara Therapeutics
TARA
$228M
$2.79M 0.03%
7,465
– –
CBIO
75
Crescent Biopharma
CBIO
$637M
$2.73M 0.02%
3,812
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2016 Portfolio in Review

As of Q3 2016, Julian Baker held 140 positions worth $11B, up 16% from $9.54B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Julian Baker withdrew a net $1.03B in Q3 2016, closing 6 positions and reducing 16 holdings. Its most notable exit was XENOPORT, INC., an estimated $24.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in ContraFect Corporation worth $10M.

  • Julian Baker's largest Q3 2016 buy was ContraFect Corporation: 5,057 shares worth $10M.
  • Julian Baker added most to Amarin Corp in Q3 2016, an estimated $55.6M increase.
  • Julian Baker's biggest Q3 2016 reduction was BioCryst Pharmaceuticals, cutting an estimated $16.2M.
  • Julian Baker fully exited XENOPORT, INC. in Q3 2016, selling an estimated $24.5M.
  • Julian Baker's ten largest holdings make up 83% of its $11B portfolio in Q3 2016.
  • Julian Baker opened 7 new positions and closed 6 in Q3 2016.
  • Julian Baker's portfolio value rose 16% quarter-over-quarter to $11B.

Based on Baker Bros. Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.